Preparation method of cleaning perfusate for cerebrospinal cord operation and container of cleaning perfusate
By preparing solutions A and B in a dual-chamber soft bag, the problem of the lack of suitable cleaning and perfusion solutions for neurosurgical procedures in the prior art is solved. A perfusion solution with a composition similar to human cerebrospinal fluid is provided, ensuring that the electrolyte composition and pH value are close to CSF, reducing the frequency of drug replacement, and improving surgical efficiency and solution stability.
Patent Information
- Application Number
- CN202411224372.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-03
- Publication Date
- 2024-11-08
AI Technical Summary
The existing technology lacks cleaning and perfusion fluids suitable for neurosurgical procedures, and the composition of existing artificial cerebrospinal fluid does not match that of human cerebrospinal fluid, leading to the problem of frequent drug changes during clinical use.
A washing and perfusion solution with a composition similar to normal human cerebrospinal fluid was prepared. Solution A and solution B were stored in a double-chamber soft bag and sealed with non-PVC material and a high-barrier bag to ensure the stability and safety of the solution. During mixing, the two chambers were squeezed or connected to achieve uniform mixing.
This invention provides an perfusion fluid that closely resembles the composition of normal human cerebrospinal fluid (CSF), which can replace the CSF lost during surgery, ensuring that the electrolyte composition and pH value are close to CSF, reducing the need for frequent drug changes in clinical use, and improving surgical efficiency and solution stability.
Smart Images

Figure CN118903197A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of preparation of cleaning perfusion fluid for cerebrospinal surgery, in particular to a preparation method of cleaning perfusion fluid for cerebrospinal surgery and a container thereof. Background Art
[0002] The use of cleaning fluid is essential in craniotomy, spinal cord disease surgery, blood removal during bleeding, brain when using surgical coagulation devices, to prevent spinal cord tissue burns and to remove air during dural closure. In addition, in neuroendoscopic surgery, the use of perfusion fluid is essential to ensure a clear field of view during intraventricular operations. At present, there are no drugs approved in China as cleaning and perfusion fluids during surgery in the field of neurosurgery.
[0003] These are used for cleaning and infusion in neurosurgery and spinal cord disease surgery to replace the cerebrospinal fluid (CSF) lost during surgery. Since it becomes a supplemental fluid, it comes into contact with the central nervous tissue of the brain and spinal cord and is eventually recycled into the blood. Therefore, it is hoped that its electrolyte composition and pH are close to those of CSF.
[0004] After searching, there are disclosures about artificial cerebrospinal fluid in the prior art, such as Patent Document 1, Artificial Cerebrospinal Fluid-WO2006115057A1, Patent Document 2, Artificial Cerebrospinal Fluid-AU2006240846A1 and Patent Document 3, Artificial Spinal Fluid-TW095113646, all of which use artificial cerebrospinal fluid with similar composition and properties to normal human cerebrospinal fluid for the purpose of flushing, cleaning or perfusion, or for the purpose of replenishing cerebrospinal fluid loss. Summary of the invention
[0005] The object of the present invention is to provide a method for preparing a washing perfusate for cerebrospinal surgery and a container thereof, wherein the washing perfusate for cerebrospinal surgery is a preparation similar to the composition and properties of normal human cerebrospinal fluid, containing Na + , K + Mg 2+ , Ca 2+ , Cl - 、HCO3 - and P and glucose, the pH value is about 7.3. In addition, the maximum volume of this product during clinical use is 4000ml. In order to avoid frequent changes of drugs during clinical use, the specifications of this product are adjusted to 2000ml.
[0006] To achieve the above object, the present invention provides the following technical solutions:
[0007] In a first aspect, an embodiment of the present invention provides a method for preparing a washing perfusion fluid for cerebrospinal surgery, comprising the following steps:
[0008] S1: Prepare solution A and solution B that meet the requirements;
[0009] The preparation process of the A solution is as follows: take a certain amount of water for injection, cool it to 50°C to 60°C, add dilute hydrochloric acid to adjust the pH of the solution to within the range of 4.0 to 4.5, then add sodium chloride, calcium chloride, magnesium chloride and glucose, stir and dissolve thoroughly, continue to add water for injection, and finally turn on the circulation pump, cool it to 40°C to 50°C, and obtain a colorless and clear liquid. The stability of glucose during sterilization can be guaranteed under acidic environmental conditions. This is because glucose molecules contain multiple hydroxyl groups, which are prone to hydrolysis and oxidation reactions. Under acidic conditions, the hydrogen ion concentration is high, which can inhibit the hydrolysis reaction of the hydroxyl groups in the glucose molecules. In addition, the solubility of oxygen is low under acidic conditions, which can reduce the contact between glucose molecules and oxygen, thereby reducing the occurrence of its oxidation reaction.
[0010] The preparation process of the B solution is as follows: take a certain amount of water for injection, cool it to 50℃~60℃, pass carbon dioxide gas, add sodium chloride, potassium chloride, potassium dihydrogen sulfate, sodium bicarbonate, stir and fully dissolve, continue to add water for injection, and then pass carbon dioxide gas to adjust the pH value of the solution to 7.1~7.6, start the circulation pump, cool it to 40℃~50℃, and obtain a colorless and clear liquid. The alkaline environment can ensure the stability of sodium bicarbonate. The drug needs to ensure that the content is 95-105% to achieve the drug effect. This is because sodium bicarbonate is easily decomposed into sodium carbonate and water in water. Under alkaline conditions, the concentration of hydroxide ions is high, which can inhibit the hydrogen ions in the sodium bicarbonate molecules from combining with carbonate ions, thereby reducing the occurrence of its decomposition reaction.
[0011] S2: filling the prepared solution A and solution B into the first chamber 1 and the second chamber 2 of the inner soft bag respectively, wherein the first chamber 1 and the second chamber 2 are two independent chambers; then vacuumizing the chamber filled with solution B, introducing carbon dioxide gas, and installing an infusion plug on the container packaging body;
[0012] S3: Use the outer bag film to pack the inner soft bag, then sterilize it and pack it into boxes for storage;
[0013] S4: After squeezing to connect the first chamber 1 with the second chamber 1, the A solution and the B solution are evenly mixed to obtain a clean perfusion solution, which is used to flush or perfuse the skull or spinal cavity of a brain surgery patient, or to supplement the cerebrospinal fluid loss of a brain surgery patient.
[0014] The advantages of the dual-chamber packaging soft bag design are:
[0015] 1. Independent chamber:
[0016] Two independent chambers store solution A and solution B respectively: this can effectively prevent solution A and solution B from mixing during storage and transportation, thereby ensuring the stability and effectiveness of the solutions.
[0017] Avoid cross contamination: Independent chambers can avoid cross contamination between solution A and solution B, thus ensuring the purity of the solutions.
[0018] Convenient mixing: When the perfusion fluid is needed, solution A and solution B can be mixed evenly by squeezing or connecting the two chambers, which is convenient for use.
[0019] 2. Non-PVC material:
[0020] Barrier properties: Non-PVC materials have good barrier properties and can effectively block the influence of external factors such as oxygen, moisture and light on the solution, thereby ensuring the stability and safety of the solution.
[0021] Heat resistance: Non-PVC materials are not easily deformed and decomposed at high temperatures, which can ensure the safety of the solution during the sterilization process.
[0022] Chemical stability: Non-PVC materials have good tolerance to chemicals and are not easy to react with the components in the solution, thus ensuring the stability of the solution.
[0023] 3. High barrier bag closure:
[0024] Prevent increased water permeability and air permeability: The water permeability and air permeability of the double-chamber packaging soft bag material will increase under high temperature and high pressure. Therefore, it is necessary to use a high-barrier bag to seal the double-chamber packaging soft bag material before sterilization to prevent external factors from affecting the solution.
[0025] 4. Double-layer structure:
[0026] Inner soft bag film: Made of non-PVC three-layer or five-layer co-extruded film, it has good barrier properties and stability.
[0027] Outer bag film: It includes an inner polypropylene layer, a middle polyamide layer, and an outer polyester and aluminum oxide mixed layer, which can effectively block air from entering the bag, prevent the loss of carbon dioxide in the bag, and maintain a dynamic balance of the liquid medicine.
[0028] 5. Connectivity:
[0029] Squeeze or connect the two chambers: When the perfusion fluid is needed, the A solution and the B solution can be mixed evenly by squeezing or connecting the two chambers, which is convenient for use.
[0030] In an achievable manner of the first aspect, the relative labeled content of glucose in the A solution is 95% to 105%;
[0031] And / or, the total volume of solution A added into the first cavity 1 is 600 ml.
[0032] In a manner that can be implemented in the first aspect, the mass ratio of sodium chloride, calcium chloride, magnesium chloride and glucose in the A solution is 1.08kg~1.32kg: 76.5g~93.5g: 99g~121g: 274.5g~335.5g.
[0033] In an achievable manner of the first aspect, the relative labeled content of glucose in the B solution is 95% to 105%;
[0034] And / or, the total volume of solution B added into the second cavity 2 is 1400 ml.
[0035] In a manner that can be implemented in the first aspect, the mass ratio of sodium chloride, potassium chloride, potassium dihydrogen sulfate, and sodium bicarbonate in the B solution is 2.138Kg~2.612Kg: 58.5g~71.5g: 67.5g~82.5g: 873g~1067g.
[0036] In a manner that can be implemented in the first aspect, when preparing the A solution or the B solution, after starting the circulation pump, the liquid circulates through the polypropylene or nylon filter element for 15 minutes to 25 minutes.
[0037] In an achievable manner of the first aspect, the pore size of the polypropylene or nylon filter element is 0.45 um.
[0038] In a manner that can be realized in the first aspect, the bag making and filling linkage line is started to prepare the inner soft bag, and the following parameters are set: the tube preheating temperature is 120° C. to 140° C., and the preheating time is 1.5s to 2s;
[0039] The heat sealing temperature of the mouth tube is 119℃~140℃, and the time is 1.4s~1.8s;
[0040] The peripheral heat sealing pressure is 4.5Mpa~5.0Mpa, the temperature is 120~140℃ and the time is 0.8s~1.2s;
[0041] The sealing time of the inner soft bag film is 1.2s to 1.6s. After the bag is qualified, it is filled.
[0042] In the second aspect, the present invention provides a container filled with a cleaning perfusion fluid for cerebrospinal cord surgery, comprising a first chamber 1 and a second chamber 2, wherein the first chamber 1 and the second chamber 2 are two independent chambers, and the first chamber 1 and the second chamber 2 are respectively filled with a solution A and a solution B, wherein the solution A and the solution B are made using the above-mentioned method for preparing the cleaning perfusion fluid for cerebrospinal cord surgery.
[0043] In an achievable manner of the second aspect, the container filled with the cleaning perfusion solution for cerebrospinal cord surgery is a double-layer structure, which includes an inner soft bag film and an outer bag film;
[0044] The material of the inner soft bag film is a non-PVC three-layer or five-layer co-extruded film. The non-PVC material has good barrier properties, heat resistance and chemical stability, and can effectively block the influence of external factors such as oxygen, moisture and light on the solution, thereby ensuring the stability and safety of the solution. In addition, the non-PVC material is environmentally friendly and easy to recycle.
[0045] The outer bag film includes an inner polypropylene layer, a middle polyamide layer, and an outer polyester and aluminum oxide mixed layer. The outer bag film is a barrier film that blocks air from entering the bag and prevents the loss of carbon dioxide in the bag, so that the drug solution can maintain a dynamic balance.
[0046] Compared with the prior art, the present invention has the following beneficial effects:
[0047] (1) Currently, there are no drugs approved in the country for use as cleaning and perfusion fluids during neurosurgery. Cleansing fluids are essential for craniotomy, spinal cord disease surgery, blood removal during bleeding, brain surgery when coagulation devices are used, and air removal during spinal cord tissue burn prevention and dural closure. In addition, in neuroendoscopic surgery, the use of perfusion fluids is essential to ensure a clear field of view during intraventricular operations.
[0048] (2) The present invention can be used for cleaning and infusion in brain and nerve surgery and spinal cord disease surgery to replace cerebrospinal fluid (CSF) lost during surgery. Since it becomes a supplementary fluid, it comes into contact with the central nervous tissue of the brain and spinal cord and is eventually recovered into the blood. Therefore, its electrolyte composition and pH are close to those of CSF.
[0049] (3) The washing perfusion fluid for cerebrospinal surgery provided by the present invention is a preparation similar to the composition and properties of normal human cerebrospinal fluid, containing Na + , K + Mg 2+ , Ca 2+ , Cl - 、HCO3 - and P and glucose, with a pH of about 7.3.
[0050] (4) To avoid frequent replacement of drugs during clinical use, the present invention adjusts the specification of this product to 2000ml, wherein the first chamber solution is 600ml, and the second chamber solution is 1400ml. When in use, the left and B solutions are mixed evenly by squeezing the middle virtual weld before use.
[0051] (5) The present invention obtains the best production process through continuous exploration through small-scale trials; and during the preparation process, the pH value of B is adjusted to control the quality of the drug. Carbon dioxide gas needs to be introduced into B solution first to drive away the dissolved oxygen in the water and the residual oxygen in the preparation tank, and is controlled by a detection method to ensure the quality and stability of the product preparation.
[0052] (6) The composition of the washing perfusate for brain and spinal cord surgery in the present invention is close to human cerebrospinal fluid, which can effectively replace the cerebrospinal fluid lost during surgery and replenish the cerebrospinal fluid loss. The A solution and the B solution are stored separately, and their stability is ensured by a double-chamber packaging soft bag and appropriate sterilization conditions. In addition, the double-chamber structure can conveniently mix the A solution and the B solution for use, thereby improving the efficiency of the operation. BRIEF DESCRIPTION OF THE DRAWINGS
[0053] Figure 1 This is a schematic diagram of a preferred embodiment of the structure of a container package for a washing and perfusion solution for cerebrospinal cord surgery provided by the present invention. Description of the drawings:
[0055] 1. First chamber; 2. Second chamber. DETAILED DESCRIPTION
[0056] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0057] Example 1: Please refer to Figure 1 The present invention provides a method for preparing a cleaning perfusion fluid for cerebrospinal cord surgery, including a method for preparing solution A and a method for preparing solution B and a filling method. The prepared solution A and solution B are simultaneously placed in a double-chamber packaging soft bag, and the double-chamber packaging soft bag includes a chamber for storing solution A and a chamber for storing solution B.
[0058] The preparation method of solution A is as follows:
[0059] (1) The raw materials for preparing 1500 bags of solution A include: 7.20 kg of sodium chloride, 0.51 kg of calcium chloride, 0.66 kg of magnesium chloride, 1.83 kg of glucose, adjusted to pH 4.0-4.5 with appropriate amount of dilute hydrochloric acid and water for injection to 900 L;
[0060] First, take 810L of water for injection and cool the temperature to 50℃, add appropriate amount of dilute hydrochloric acid to adjust the test pH to 4.0, then add the above-prescribed amount of sodium chloride, calcium chloride, magnesium chloride, and glucose, stir to fully dissolve, and continue to add sufficient water for injection after complete dissolution; turn on the circulation pump, circulate through a 0.45um polypropylene or nylon filter element for 15 minutes, cool to 40℃, and obtain a colorless, clear liquid with a glucose content of 95% to 105% relative to the labeled content. After passing the test, it will be filled.
[0061] Table 1 Intermediate test results
[0062] Test items Characteristics pH Glucose content Test results Colorless clear liquid 4.02 99.8%
[0063] It can be seen from Table 1 that according to the established preparation method, the properties and pH of the intermediate product A solution meet the requirements, and the relative labeled content of glucose is close to 100%, which can ensure the therapeutic efficacy of the product, indicating that a qualified intermediate product A can be produced according to the method of the present invention.
[0064] Preparation of solution B:
[0065] (1) 1500 bags of solution B were prepared with the following raw materials: 14.25 kg sodium chloride, 0.39 kg potassium chloride, 0.45 kg potassium dihydrogen sulfate, 5.82 kg sodium bicarbonate, carbon dioxide was added to adjust the pH to 7.1-7.6, and water for injection was added to make up to 2100 L;
[0066] First, take 1800L of water for injection, cool it to 50℃, pass carbon dioxide gas, and the residual oxygen result is less than 1% to 3%. Then add the prescribed amount of sodium chloride, potassium chloride, potassium dihydrogen sulfate, and sodium bicarbonate, stir to fully dissolve, and continue to add sufficient water for injection after complete dissolution, and then pass carbon dioxide to adjust the pH value to 7.1; turn on the circulation pump, circulate through a 0.45um polypropylene or nylon filter element for 15 minutes, cool to 40℃, and the property is a colorless, clear liquid. The solution with a sodium bicarbonate content of 95% to 105% relative to the labeled content is qualified and ready for filling.
[0067] Table 2 Intermediate test results
[0068]
[0069]
[0070] It can be seen from Table 2 that according to the established preparation method, the properties and pH of the intermediate product of solution B meet the requirements, and the relative labeled content of sodium bicarbonate is close to 100%, which can ensure the therapeutic efficacy of the product, indicating that qualified products can be produced according to the production method of the present invention.
[0071] In view of the fact that the water permeability and air permeability of the double-chamber packaging soft bag material increase under high temperature and high pressure, a high barrier bag is used to seal the double-chamber packaging soft bag material before sterilization.
[0072] The double-chamber packaging soft bag used in this application can use a non-PVC three-layer or five-layer co-extruded film, preferably a non-PVC three-layer. This application preferably uses a film with an inner layer of a polypropylene layer, a middle layer of a polyamide layer, and an outer layer of a polyester and aluminum oxide layer, which can prevent gas exchange inside and outside the soft bag during high-temperature sterilization and ensure the stability of the product for long-term storage. Solution A and solution B are packaged in a double-chamber packaging soft bag, as shown in the figure. Figure 1 .
[0073] Filling method of double chamber packaging soft bag:
[0074] I. Start the bag making and filling line and set the following parameters:
[0075] a. Tube preheating: set the temperature to 120°C and the time to 1.5S;
[0076] b. Heat sealing of tubes: set the temperature to 119°C and the time to 1.4S;
[0077] c. Peripheral heat sealing: set the pressure to 4.5Mpa, the temperature to 120℃, and the time to 0.8S;
[0078] d. Sealing the inner soft bag film: time 1.2S. After the bag is qualified, first fill the samples prepared in step (1) of solution A and step (1) of solution B into their respective chambers, then evacuate for 2S, then fill with carbon dioxide for 2S, and add an infusion stopper;
[0079] e. Light inspection, outer bag film, sterilization, and the sterilization temperature is set to 121℃, and the constant temperature sterilization is carried out for 10 minutes, and finally packing. The sterilization conditions of 121℃ and 10 minutes can effectively kill bacteria and viruses in the solution and ensure the sterility of the solution. In addition, since the sterilization temperature of 121℃ is high, but the sterilization time of 10 minutes is short, it can effectively avoid the degradation of the components in the solution.
[0080] Table 3 Stability test results of Example 1
[0081]
[0082] From the results in Table 3, it can be seen that after 24 months of long-term experiment, the neutral properties and pH of solution A, solution B and the mixed posterior brain spinal cord surgery washing perfusion solution in the double-chamber soft bag packaged with solution A and solution B all meet the requirements, the content of related substances is less than 0.5%, the content is within 95% to 105% relative to the labeled content, the content does not change substantially, and the related substances are stable, indicating that the product produced according to the method of the present invention has good stability.
[0083] Example 2: The preparation method in this example is basically the same as that in Example 1, except that the preparation method of solution A in this example is:
[0084] The raw materials for preparing 2000 bags of solution A include: 9.60kg sodium chloride, 0.68kg calcium chloride, 0.88kg magnesium chloride, 2.44kg glucose, adjusted to pH 4.0-4.5 with appropriate amount of dilute hydrochloric acid and water for injection to 1200L;
[0085] First, take 1080L of water for injection and cool the temperature to 55℃, add appropriate amount of dilute hydrochloric acid to adjust the test pH to 4.3, then add the above-prescribed amount of sodium chloride, calcium chloride, magnesium chloride, and glucose, stir to fully dissolve, and continue to add sufficient water for injection after complete dissolution; turn on the circulation pump, circulate through a 0.45um polypropylene or nylon filter element for 20 minutes, cool to 45℃, and obtain a colorless, clear liquid with a glucose content of 95% to 105% relative to the labeled content. After passing the test, it will be filled.
[0086] Table 4 Intermediate detection results
[0087] Test items Characteristics pH Glucose content Test results Colorless clear liquid 4.23 99.7%
[0088] It can be seen from Table 4 that according to the established preparation method, the properties and pH of the intermediate product A solution meet the requirements, and the relative labeled content of glucose is close to 100%, which can ensure the therapeutic efficacy of the product, indicating that a qualified intermediate product A can be produced according to the method of the present invention.
[0089] Preparation of solution B:
[0090] The raw materials for preparing 2000 bags of solution B include: 19.00kg sodium chloride, 0.52kg potassium chloride, 0.60kg potassium dihydrogen sulfate, 7.76kg sodium bicarbonate, carbon dioxide is introduced to adjust the pH to 7.1-7.6, and water for injection is added to 2800L;
[0091] First, take 2520L of water for injection, cool it to 55℃, pass carbon dioxide gas, and the residual oxygen result is less than 1% to 3%. Then add the prescribed amount of sodium chloride, potassium chloride, potassium dihydrogen sulfate, and sodium bicarbonate, stir to fully dissolve, and continue to add sufficient water for injection after complete dissolution, and then pass carbon dioxide to adjust the pH value to 7.4; turn on the circulation pump, circulate through a 0.45um polypropylene or nylon filter element for 20 minutes, cool to 45℃, and the property is a colorless, clear liquid. The relative labeled content of sodium bicarbonate is 95% to 105%. After passing the test, it will be filled.
[0092] Table 5 Intermediate detection results
[0093] Test items Characteristics pH Sodium bicarbonate content Test results Colorless clear liquid 7.40 100.1%
[0094] It can be seen from Table 5 that according to the established preparation method, the properties and pH of the intermediate product of solution B meet the requirements, and the relative labeled content of sodium bicarbonate is close to 100%, which can ensure the therapeutic efficacy of the product, indicating that qualified products can be produced according to the production method of the present invention.
[0095] In view of the fact that the water permeability and air permeability of the double-chamber packaging soft bag material increase under high temperature and high pressure, a high barrier bag is used to seal the double-chamber packaging soft bag material before sterilization.
[0096] The double-chamber packaging soft bag used in this application can use a non-PVC three-layer or five-layer co-extruded film, preferably a non-PVC three-layer. This application preferably uses a film with an inner layer of a polypropylene layer, a middle layer of a polyamide layer, and an outer layer of a polyester and aluminum oxide layer, which can prevent gas exchange inside and outside the soft bag during high-temperature sterilization and ensure the stability of the product for long-term storage. Solution A and solution B are packaged in a double-chamber packaging soft bag, as shown in the figure. Figure 1 .
[0097] Filling method of double chamber packaging soft bag:
[0098] II. Start the bag making and filling line and set the following parameters:
[0099] f. Tube preheating: set the temperature to 130°C and the time to 2.0S;
[0100] g. Heat sealing of mouth and tube: temperature 125℃, time 1.6S;
[0101] h. Peripheral heat sealing: pressure 4.8Mpa, temperature 130℃, time 1.0S;
[0102] i. Sealing the inner soft bag film: Set the time to 1.4 seconds. After the bag is qualified, first fill the samples prepared in step (2) of solution A and step (2) of solution B into their respective chambers, then evacuate for 3 seconds, then fill with nitrogen for 3 seconds, and add an infusion stopper;
[0103] j. Light inspection, outer bag film wrapping, sterilization, and the sterilization temperature is 121℃, and the constant temperature sterilization is 12 minutes, and finally packing;
[0104] Table 6 Stability test results of Example 2
[0105]
[0106]
[0107] From the results in Table 6, it can be seen that after 24 months of long-term experiment, the neutral properties and pH of solution A, solution B and the mixed posterior brain spinal cord surgery washing perfusion solution in the double-chamber soft bag packaged with solution A and solution B all met the requirements, the content of related substances was less than 0.5%, and the content relative to the labeled content was within 95% to 105%, indicating that the product produced according to the method of the present invention has good stability.
[0108] Example 3: The preparation method in this example is basically the same as that in Example 1, except that the preparation method of solution A in this example is:
[0109] The raw materials for preparing 2500 bags of solution A include: 12.00kg sodium chloride, 0.85kg calcium chloride, 1.10kg magnesium chloride, 3.05kg glucose, adjusted to pH 4.0-4.5 with appropriate amount of dilute hydrochloric acid and water for injection to 1500L;
[0110] First, take 1350L of water for injection and cool the temperature to 60℃, add appropriate amount of dilute hydrochloric acid to adjust the test pH to 4.5, then add the above-prescribed amount of sodium chloride, calcium chloride, magnesium chloride, and glucose, stir to fully dissolve, and continue to add sufficient water for injection after complete dissolution; turn on the circulation pump, circulate through a 0.45um polypropylene or nylon filter element for 25 minutes, cool to 50℃, and obtain a colorless, clear liquid with a glucose content of 95% to 105% relative to the labeled content. After passing the test, it will be filled.
[0111] Table 7 Intermediate detection results
[0112] Test items Characteristics pH Glucose content Test results Colorless clear liquid 4.50 99.2%
[0113] It can be seen from Table 7 that according to the established preparation method, the properties and pH of the intermediate product A solution meet the requirements, and the relative labeled content of glucose is close to 100%, which can ensure the therapeutic efficacy of the product, indicating that a qualified intermediate product A can be produced according to the method of the present invention.
[0114] Preparation of solution B:
[0115] The raw materials for preparing 2500 bags of solution B include: 23.75kg sodium chloride, 0.65kg potassium chloride, 0.75kg potassium dihydrogen sulfate, 9.70kg sodium bicarbonate, carbon dioxide is introduced to adjust the pH to 7.1-7.6, and water for injection is added to 3500L;
[0116] First, take 3150L of water for injection, cool it to 60℃, pass carbon dioxide gas, and the residual oxygen result is less than 1% to 3%. Then add the prescribed amount of sodium chloride, potassium chloride, potassium dihydrogen sulfate, and sodium bicarbonate, stir to fully dissolve, and continue to add sufficient water for injection after complete dissolution, and then pass carbon dioxide to adjust the pH value to 7.6; turn on the circulation pump, circulate through a 0.45um polypropylene or nylon filter element for 25 minutes, cool to 50℃, and the property is a colorless, clear liquid. The relative labeled content of sodium bicarbonate is 95% to 105%. After passing the test, it will be filled.
[0117] Table 8 Intermediate detection results
[0118] Test items Characteristics pH Sodium bicarbonate content Test results Colorless clear liquid 7.59 99.8%
[0119] It can be seen from Table 8 that according to the established preparation method, the properties and pH of the intermediate product of solution B meet the requirements, and the relative labeled content of sodium bicarbonate is close to 100%, which can ensure the therapeutic efficacy of the product, indicating that qualified products can be produced according to the production method of the present invention.
[0120] In view of the fact that the water permeability and air permeability of the double-chamber packaging soft bag material increase under high temperature and high pressure, a high barrier bag is used to seal the double-chamber packaging soft bag material before sterilization.
[0121] The double-chamber packaging soft bag used in this application can use a non-PVC three-layer or five-layer co-extruded film, preferably a non-PVC three-layer. This application preferably uses a film with an inner layer of a polypropylene layer, a middle layer of a polyamide layer, and an outer layer of a polyester and aluminum oxide layer, which can prevent gas exchange inside and outside the soft bag during high-temperature sterilization and ensure the stability of the product for long-term storage. Solution A and solution B are packaged in a double-chamber packaging soft bag, as shown in the figure. Figure 1 .
[0122] Filling method of double chamber packaging soft bag:
[0123] III. Start the bag making and filling linkage line and set the following parameters respectively:
[0124] k. Tube preheating: set the temperature to 140°C and the time to 2.5S;
[0125] 1. Heat sealing of mouth and tube: temperature 130℃, time 1.8S;
[0126] m. Peripheral heat sealing: pressure 5.0Mpa, temperature 140℃, time 1.2S;
[0127] n. Sealing the inner soft bag film: Set the time to 1.6 seconds. After the bag is qualified, first fill the samples prepared in step (3) of solution A and step (3) of solution B into their respective chambers, then evacuate for 3 seconds, then fill with nitrogen for 3 seconds, and add an infusion stopper;
[0128] o. Light inspection, outer bag film wrapping, sterilization, and the sterilization temperature is 121℃, and the constant temperature sterilization is carried out for 15 minutes, and finally packing;
[0129] Table 9 Stability test results of Example 3
[0130]
[0131]
[0132] From the results in Table 9, it can be seen that after 24 months of long-term experiment, the neutral properties and pH of solution A, solution B and the mixed posterior brain spinal cord surgery washing perfusion solution in the double-chamber soft bag packaged with solution A and solution B all met the requirements, the content of related substances was less than 0.5%, and the content relative to the labeled content was within 95% to 105%, indicating that the product produced according to the method of the present invention has good stability.
[0133] It will be apparent to those skilled in the art that the invention is not limited to the details of the exemplary embodiments described above and that the invention can be implemented in other specific forms without departing from the spirit or essential features of the invention. Therefore, the embodiments should be considered exemplary and non-limiting in all respects, and the scope of the invention is defined by the appended claims rather than the foregoing description, and it is intended that all variations falling within the meaning and scope of the equivalent elements of the claims be included in the invention. Any reference numeral in a claim should not be considered as limiting the claim to which it relates.
Claims
1. A method for preparing a washing perfusion fluid for cerebrospinal surgery, characterized in that: The following steps are involved: S1: Prepare solution A and solution B that meet the requirements; The preparation process of the A solution is as follows: take a certain amount of water for injection, cool it to 50°C to 60°C, add dilute hydrochloric acid to adjust the pH of the solution to within the range of 4.0 to 4.5, then add sodium chloride, calcium chloride, magnesium chloride and glucose, stir and dissolve them thoroughly, continue to add water for injection, and finally start the circulation pump, cool it to 40°C to 50°C, and obtain a colorless clear liquid; The preparation process of the B solution is as follows: take a certain amount of water for injection, cool it to 50°C to 60°C, pass carbon dioxide gas, and add sodium chloride, potassium chloride, potassium dihydrogen sulfate, and sodium bicarbonate. After stirring and fully dissolving, continue to add water for injection, and then pass carbon dioxide gas to adjust the pH value of the solution to the range of 7.1 to 7.6, start the circulation pump, cool it to 40°C to 50°C, and obtain a colorless and clear liquid; S2: filling the prepared solution A and solution B into the first chamber (1) and the second chamber (2) of the inner soft bag respectively, wherein the first chamber (1) and the second chamber (2) are two independent chambers; then vacuumizing the chamber filled with solution B, introducing carbon dioxide gas, and installing an infusion plug on the container packaging body; S3: Use the outer bag film to pack the inner soft bag, then sterilize it and pack it into boxes for storage; S4: After squeezing to connect the first chamber (1) and the second chamber (2), the A solution and the B solution are evenly mixed to obtain a clean perfusion solution, which is used to flush or perfuse the skull or spinal cavity of a brain surgery patient, or to supplement the cerebrospinal fluid loss of a brain surgery patient.
2. The method for preparing a washing perfusate for cerebrospinal surgery according to claim 1, characterized in that: The relative labeled content of glucose in the A solution is 95% to 105%; And / or, the total volume of solution A added into the first cavity (1) is 600 ml.
3. The method for preparing a washing perfusate for cerebrospinal surgery according to claim 1, characterized in that: The mass ratio of sodium chloride, calcium chloride, magnesium chloride and glucose in the solution A is 1.08kg-1.32kg: 76.5g-93.5g: 99g-121g: 274.5g-335.5g.
4. The method for preparing a washing perfusate for cerebrospinal surgery according to claim 1, characterized in that: The relative labeled content of glucose in the B solution is 95% to 105%; And / or, the total volume of solution B added into the second cavity (2) is 1400 ml.
5. The method for preparing a washing perfusate for cerebrospinal cord surgery according to claim 1, characterized in that: The mass ratio of sodium chloride, potassium chloride, potassium dihydrogen sulfate and sodium bicarbonate in the B solution is 2.138Kg-2.612Kg: 58.5g-71.5g: 67.5g-82.5g: 873g-1067g.
6. The method for preparing a washing perfusate for cerebrospinal cord surgery according to claim 1, characterized in that: When preparing the A solution or the B solution, after starting the circulation pump, the liquid circulates through the polypropylene or nylon filter element for 15 minutes to 25 minutes.
7. The method for preparing a washing perfusate for cerebrospinal cord surgery according to claim 6, characterized in that: The pore size of the polypropylene or nylon filter element is 0.45um.
8. The method for preparing a washing perfusate for cerebrospinal cord surgery according to any one of claims 1 to 7, characterized in that: Start the bag-making and filling line to prepare the inner soft bag, and set the following parameters: tube preheating temperature is 120℃~140℃, preheating time is 1.5s~2s; The heat sealing temperature of the mouth tube is 119℃~140℃, and the time is 1.4s~1.8s; The peripheral heat sealing pressure is 4.5Mpa~5.0Mpa, the temperature is 120~140℃ and the time is 0.8s~1.2s; The sealing time of the inner soft bag film is 1.2s to 1.6s. After the bag is qualified, the filling process is carried out.
9. A container filled with a cleaning perfusion solution for cerebrospinal surgery, characterized in that: The invention comprises a first chamber (1) and a second chamber (2), wherein the first chamber (1) and the second chamber (2) are two independent chambers, and the first chamber (1) and the second chamber (2) are respectively filled with a solution A and a solution B, wherein the solution A and the solution B are prepared by the method for preparing a washing perfusion fluid for cerebrospinal cord surgery according to any one of claims 1 to 8.
10. The container filled with a washing perfusion solution for cerebrospinal surgery according to claim 9, characterized in that: The container filled with the cleaning perfusion solution for cerebrospinal cord surgery has a double-layer structure, including an inner soft bag film and an outer bag film; The material of the inner soft bag film is a non-PVC three-layer or five-layer co-extruded film; The outer bag film comprises an inner polypropylene layer, a middle polyamide layer, and an outer polyester and aluminum oxide mixed layer.
Citation Information
Patent Citations
Artificial cerebrospinal fluid
AU2006240846A1
Artificial cerebrospinal fluid
WO2006115057A1
